Clinical trial / 2015
In patients with Alzheimer disease, 52 weeks of resveratrol treatment was safe, well-tolerated, altered Aβ40 trajectories, and increased brain volume loss.
In a 52-week phase 2 trial, 119 participants with mild to moderate Alzheimer disease were randomized to placebo or oral resveratrol (dose-escalated from 500 mg daily to 1,000 mg twice daily). Resveratrol and its major metabolites penetrated the blood-brain barrier. The most frequent adverse events were nausea, diarrhea, and weight loss. CSF Aβ40 and plasma Aβ40 levels declined more in the placebo group than in the resveratrol group, producing a significant difference at week 52, while brain volume loss was increased with resveratrol compared to placebo.
- Study type
- Randomized, double-blind, placebo-controlled phase 2 trial
- Who was studied
- 119 individuals with mild to moderate Alzheimer disease
- What was measured
- Safety, tolerability, plasma and CSF biomarkers (Aβ40, Aβ42, tau, phospho-tau 181), volumetric MRI outcomes, and clinical outcomes
THE PAPER
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.
Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, Alzheimer's Disease Cooperative Study. Neurology, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.